LANGE LOUIS G — SEC Form 4 filings
SEC reporting owner CIK 1238401. 9 Form 4 filings on record with FilingPulse; latest filed 2026-03-12.
Transaction summary — filings shown
Covers all 9 filings on record, filed 2024-02-21 to 2026-03-12. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 1 leg across 1 filing — 5,000 shares, $95,000 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 3 legs across 2 filings — 72,805 shares, $2,186,180 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 15.
- Largest priced transaction: sale of 44,173 shares @ $30.41 ($1,343,301) in NewAmsterdam Pharma Co N.V., filed 2026-03-12.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | Director | 9 | 1 leg · 5,000 sh · $95,000 | 3 legs · 72,805 sh · $2,186,180 | 15 |
Form 4 filings — LANGE LOUIS G
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-03-12 | 4 | NewAmsterdam Pharma Co N.V. (NAMS) | Sale (S): 44,173 @ $30.41 · Sale (S): 446 @ $31.23 | EDGAR |
| 2026-03-10 | 4 | NewAmsterdam Pharma Co N.V. (NAMS) | Sale (S): 28,186 @ $29.41 · Option exercise/expiry (X): 44,619 @ $11.50 · Option exercise/expiry (X): 44,619 (derivative) @ $0 | EDGAR |
| 2026-01-09 | 4 | NewAmsterdam Pharma Co N.V. (NAMS) | Grant/award (A): 3,400 · Grant/award (A): 15,300 (derivative) @ $0 | EDGAR |
| 2025-06-03 | 4 | NewAmsterdam Pharma Co N.V. (NAMS) | Option exercise (M): 68 @ $0 · Option exercise (M): 68 (derivative) | EDGAR |
| 2025-05-02 | 4 | NewAmsterdam Pharma Co N.V. (NAMS) | Option exercise (M): 69 @ $0 · Option exercise (M): 69 (derivative) | EDGAR |
| 2025-04-21 | 4 | NewAmsterdam Pharma Co N.V. (NAMS) | Option exercise (M): 69 @ $0 · Option exercise (M): 69 (derivative) | EDGAR |
| 2025-03-28 | 4 | NewAmsterdam Pharma Co N.V. (NAMS) | Option exercise (M): 3,102 @ $0 · Grant/award (A): 3,308 (derivative) · Option exercise (M): 3,102 (derivative) | EDGAR |
| 2025-01-08 | 4 | NewAmsterdam Pharma Co N.V. (NAMS) | Grant/award (A): 6,960 · Grant/award (A): 32,500 (derivative) @ $0 | EDGAR |
| 2024-02-21 | 4 | NewAmsterdam Pharma Co N.V. (NAMS) | Purchase (P): 5,000 @ $19 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1238401 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →